BioCryst

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioCryst 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. 

CEO
Charles K. Gayer
CEOCharles K. Gayer
Employees
435
Employees435
Headquarters
Durham, North Carolina
HeadquartersDurham, North Carolina
Founded
1986
Founded1986
Employees
435
Employees435

BCRX Key Statistics

Market cap
2.65B
Market cap2.65B
Price-Earnings ratio
-5.88
Price-Earnings ratio-5.88
Dividend yield
Dividend yield
Average volume
6.44M
Average volume6.44M
High today
$10.84
High today$10.84
Low today
$10.28
Low today$10.28
Open price
$10.71
Open price$10.71
Volume
3.36M
Volume3.36M
52 Week high
$11.22
52 Week high$11.22
52 Week low
$6.00
52 Week low$6.00

Stock Snapshot

BioCryst(BCRX) stock is priced at $10.42, giving the company a market capitalization of 2.65B. It carries a P/E multiple of -5.88.

On 2026-07-11, BioCryst(BCRX) stock traded between a low of $10.28 and a high of $10.84. Shares are currently priced at $10.42, which is +1.4% above the low and -3.8% below the high.

BioCryst(BCRX) shares are trading with a volume of 3.36M, against a daily average of 6.44M.

During the past year, BioCryst(BCRX) stock moved between $6.00 at its lowest and $11.22 at its peak.

During the past year, BioCryst(BCRX) stock moved between $6.00 at its lowest and $11.22 at its peak.

BCRX News

Simply Wall St 2d
Is BioCryst Trading Internal Discovery for a More Durable Rare-Disease Innovation Model? - simplywall.st

...

Is BioCryst Trading Internal Discovery for a More Durable Rare-Disease Innovation Model? - simplywall.st
TipRanks 4d
Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal

Wedbush notes that Vertex Pharmaceuticals (VRTX) agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85/share in cash. Crinetics now trades essentially at t...

Simply Wall St 6d
BioCryst Pharmaceuticals Ends Internal Discovery, Is The Stock Still Undervalued?

BioCryst Pharmaceuticals (BCRX) is reshaping its research model after deciding to end internal discovery programs and close its Discovery Center of Excellence i...

BioCryst Pharmaceuticals Ends Internal Discovery, Is The Stock Still Undervalued?

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.